To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The leader of the Triad’s ...

Profit outlook tops Wall Street estimates amid strong diagnostics demand Peer growth trends also benefiting Quest Diagnostics CEO Adam Schechter cites continued growth focus for 2026 Analyst estimates ...

Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions]. Please be advised today's conference being recorded. I would now like to hand ...

Earnings call LabCorp reported Q1 2025 revenue of $3.3B (+5.3% YoY) and adjusted EPS of $3.84 (+4% YoY), driven by strong diagnostics growth and margin expansion in biopharma services. Management ...

Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection ...

Image source: The Motley Fool. Management cited the divestiture and consolidation of non-core early development sites, resulting in a reduction of approximately $50 million in annual revenue. The ...

Reports Q3 revenue $3.28B, consensus $3.26B. “Labcorp (LH) achieved strong performance in Diagnostics and Biopharma Laboratories, including robust organic growth in the third quarter,” said Adam ...

Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39. Sales increased 9.8% year-over-year to ...

Labcorp CEO Adam Schechter on Tuesday urged Americans to be vaccinated against Covid-19 and told CNBC that recipients are not being advised to be tested for Covid antibodies afterward. "At the moment, ...

Earnings call Labcorp reported Q3 2025 revenue of $3.6B (+8.6% YoY), driven by 6.2% organic growth and margin expansion. Adjusted EPS rose 19% to $4.18. Management raised full-year EPS and cash flow ...

Adam Schechter: Thank you, Christin, and good morning, everyone. We appreciate you joining us to review our fourth quarter and full year 2025 performance and our outlook for 2026. 2025 was a very ...